• Xinfeng Liu, Gelin Xu, Yuxiu Liu, Wusheng Zhu, Minmin Ma, Yunyun Xiong, Wenjie Zi, Qiliang Dai, Thomas Leung, Bernard Yan, Stephen Davis, David S Liebeskind, Vítor M Pereira, Raul G Nogueira, and BEST Trial Investigators.
• 1 Department of Neurology, Jinling Hospital, Medical School of Nanjing University, Nanjing, China.
• Int J Stroke. 2017 Oct 1; 12 (7): 779-785.

AbstractRationale Endovascular treatment plus standard medical therapy is superior to standard medical therapy alone for acute anterior proximal intracranial large artery occlusion strokes. The benefit of endovascular treatment in acute ischemic stroke caused by basilar artery occlusion remains unproven. Aim This study compares the safety and efficacy of endovascular treatment plus standard medical therapy versus standard medical therapy alone in acute ischemic stroke due to basilar artery occlusion. Design The study is a multicenter randomized control trial with blinded outcome assessment. A projected total 344 subjects with acute basilar arterial occlusion within 8 h of estimated occlusion time will be enrolled over three years in China. Patients will be assigned to endovascular treatment plus standard medical therapy and standard medical therapy alone group in 1:1 ratio for study centers. Study outcomes The primary outcome measure is a favorable functional outcome, defined as a modified Rankin Score of 0-3 at 90 days. The primary safety measure is mortality at 90 days. Trial registration ClinicalTrials.gov (NCT 02441556). Summary The BEST trial will provide valuable insights into the safety and efficacy of endovascular treatment for acute ischemic stroke patients with basilar artery occlusion.

27 keywords...

hide…